Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View
- 1.8k Downloads
To provide a definitive assessment of prediction of in vivo CL int from human liver in vitro systems for assessment of typical underprediction.
A database of published predictions of clearance from human hepatocytes and liver microsomes was compiled, including only intravenous CL b. The influence of liver model (well-stirred (WS) or parallel tube (PT)), plasma protein binding and clearance level on the relationship between in vitro and in vivo CL int was examined.
Average prediction bias was about 5- and 4-fold for microsomes and hepatocytes, respectively. Reduced bias using the PT model, in preference to the popular WS model, was only marginal across a wide range of clearance with a consequential minor impact on prediction. Increasing underprediction with decreasing fu b, or increasing CL int, was found only for hepatocytes, suggesting fundamental in vitro artefacts rather than failure to model potentially unequilibrated binding during rapid extraction.
In contrast to microsomes, hepatocytes give a disproportionate prediction with increasing clearance suggesting limitations either at the active site, such as cofactor exhaustion, or with intracellular concentration equilibrium, such as rate-limiting cell permeability. A simple log linear empirical relationship can be used to correct hepatocyte predictions.
KEY WORDSclearance hepatocytes human microsomes prediction
‘Well-stirred’ (liver model)
‘Parallel tube’ (liver model)
fraction unbound in blood
J. A. Foster was supported by funding from the EU 6th Framework Programme for Optimisation of Liver and Intestine In Vitro Models for Pharmacokinetics (Liintop/STREP 037499).
- 2.Hewitt NJ, Gomez Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev. 2007;39:159–234.CrossRefPubMedGoogle Scholar
- 8.Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, et al. Scaling factors for the extrapolation of in vivo metabolic clearance from in vitro data: reaching a concensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8:33–45.CrossRefPubMedGoogle Scholar
- 11.Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos. 2009;37:82–9.CrossRefPubMedGoogle Scholar
- 16.Stringer R. PhD Thesis. The University of Manchester (2006).Google Scholar
- 26.Donato MT, Hallifax D, Picazo L, Castell JV, Houston JB, Gomez-Lechon MJ, et al. Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam and midazolam in adenoviral P450 transfected HepG2 cells, and comparison with hepatocytes and in vivo. (submitted for publication).Google Scholar
- 27.McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, et al. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos. 2009;37:1259–68.CrossRefPubMedGoogle Scholar